Valuation: Eagle Pharmaceuticals, Inc.

Market Cap 67.92M 59.94M 56.71M 51.43M 96.43M 6.52B 97.38M 680M 262M 3.33B 255M 249M 10.71B P/E 2021
-77x
P/E 2022 10.7x
Enterprise Value 78.11M 68.93M 65.22M 59.15M 111M 7.5B 112M 782M 302M 3.83B 293M 287M 12.32B EV / Sales 2021
3.44x
EV / Sales 2022 1.23x
Free-Float
74.04%
Yield 2021 *
-
Yield 2022 -
1 day+13.89%
1 week+13.89%
Current month+10.81%
1 month+10.81%
3 months+52.99%
6 months+200.50%
Current year+46.43%
1 week 0.9
Extreme 0.9
1.02
1 month 0.16
Extreme 0.1613
1.28
Current year 0
Extreme 0.0011
1.28
1 year 0
Extreme 0.0011
3
3 years 0
Extreme 0.0011
15.7
5 years 0
Extreme 0.0011
58.25
10 years 0
Extreme 0.0011
97.15
Manager TitleAgeSince
Chief Executive Officer 63 2023-11-26
Director of Finance/CFO 52 2024-11-10
Corporate Officer/Principal - 2022-07-17
Director TitleAgeSince
Director/Board Member 83 2007-02-28
Chairman 63 2016-06-28
Director/Board Member 65 2016-06-30
Date Insider Type Main position Quantity % Market Cap. Importance
2/28/24 Tax 2,119 0.0163%
2/27/24 Free 16,104 0.1240%
2/27/24 Free

Chief Financial Officer

5,389 0.0415%
Change 5-day change 1-year change 3-year change Capi.($)
+13.89%+13.89%-62.04%-93.50% 13.35M
+0.40%-1.08%+89.97%+45.00% 367B
-0.76%+3.19%+28.05%-13.12% 68.44B
-1.18%-3.10%+52.22%+192.04% 12.81B
+0.35%+0.53%-1.09%-11.38% 7.47B
-1.71%-2.60%-25.91%-13.11% 4.39B
-2.28%-2.80%-37.23%+1.12% 4.1B
+2.62%-3.47%-25.59%-14.53% 2.99B
-1.41%+0.50%-7.63%+59.48% 2.59B
+0.31%-3.96%-20.29%-32.17% 1.89B
Average +1.10%-1.04%-0.95%+11.98% 47.15B
Weighted average by Cap. +0.76%-0.03%+74.62%+38.13%

Financials

2021 2022
Net sales 172M 151M 143M 130M 244M 16.46B 246M 1.72B 662M 8.41B 644M 630M 27.05B 317M 279M 264M 240M 449M 30.38B 454M 3.17B 1.22B 15.51B 1.19B 1.16B 49.92B
Net income -8.63M -7.61M -7.2M -6.53M -12.25M -828M -12.37M -86.41M -33.3M -423M -32.39M -31.69M -1.36B 35.64M 31.45M 29.76M 26.99M 50.6M 3.42B 51.1M 357M 138M 1.75B 134M 131M 5.62B
Net Debt -67.84M -59.87M -56.65M -51.37M -96.31M -6.51B -97.26M -680M -262M -3.32B -255M -249M -10.7B 10.19M 8.99M 8.51M 7.71M 14.46M 978M 14.61M 102M 39.33M 499M 38.25M 37.42M 1.61B
Logo Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial specializations. The Company is focused on developing medicines that result in improvements in patients' lives. The Company's commercialized products include PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO through its wholly owned subsidiary Acacia Pharma Inc. The Company’s oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Its pipeline includes ENA-001 and EA-114. EA-114 is a novel and proprietary formulation of fulvestrant being developed for hormone-receptor-positive (HR+) metastatic breast cancer. ENA-001 is an investigational new chemical entity being developed by the Company’s partner, Enalare, as an agnostic respiratory stimulant for multiple patient populations experiencing respiratory depression.
Employees
134
Date Price Change Volume
26-09-25 US$1.025 +13.89% 16,004
26-09-24 US$0.9000 0.00% 4,110
26-09-23 US$0.9000 0.00% 294
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. EGRX Stock